US5152978A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sulphated vinyl polymers in compositions for treating retroviral infections
Assignee: Stichting Rega VZW
•
Filing: 1989-02-23
•
Granted: 1992-10-06
•
Expires: 2009-02-23
Abstract
Abstract Sulphated vinyl polymers such as sulphated polyvinylalcohol, sulphated copolymers of (meth)acrylic acid and vinylalcohol, and pharmaceutically acceptable salts thereof, have an antiviral effect against human immunodeficiency virus and may therefore be used as a therapeutic agent for treating retrovirus infections like AIDS and AIDS-related diseases. Their antiviral activity is apparently based on inhibition of virus adsorption; their inhibitory effect on giant cell formation is stronger than that of dextran sulphate.
Inventors
- 👤 Masanori Baba
- 👤 Erik D. A. de Clercq
- 👤 Sandor Gorog
- 👤 Miklos Low
- 👤 Miklos Nagy
- 👤 Sandorne Gyorgyi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 10:18
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/74; A61K31/795; A61P; A61P31/00; A61P31/12; A61P31/14; A61P31/18
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
60 words
A method for the treatment of immunodeficiency diseases causally related to human immunodeficiency virus, which comprises administering an amount of a sulfated vinyl polymer selected from the group consisting of sulfated polyvinylalcohols, sulfated copolymers of (meth)acrylic acid and vinylalcohol, together with at least one pharmaceutically acceptable excipient, in an amount effective to treat a patient suffering from said immunodeficiency disease.
Claim 2
Independent Claim
60 words
A method for the treatment of immunodeficiency diseases causally related to human immunodeficiency virus, which comprises administering an amount of a sulfated vinyl polymer selected from the group consisting of sulfated polyvinylalcohols, sulfated copolymers of (meth)acrylic acid and vinylalcohol, together with at least one pharmaceutically acceptable excipient, in an amount effective to treat a patient suffering from said immunodeficiency disease.
Claim 3
Dependent Claim
29 words
The method as set forth in claim 1, wherein said sulfated vinyl polymer is a sulfated copolymer of acrylic acid and vinylalcohol in a monomer ratio of about 1:9.
Claim 4
Dependent Claim
26 words
The method as set forth in claim 2, wherein said sulfated copolymer has a molecular weight of about 10,000 and a sulfation degree of about 60%.
Claim 5
Dependent Claim
26 words
The method as set forth in claim 2, wherein said sulfated copolymer has a molecular weight of about 20,000 and a sulfation degree of about 50%.
Claim 6
Dependent Claim
31 words
The method as set forth in claim 1, wherein said sulfated vinyl polymer is a sulfated polyvinylalcohol having a molecular weight of about 20,000 and a sulfation degree of about 50%.
Claim 7
Independent Claim
24 words
The method as set forth in any of claims 1-5, wherein said sulfated vinyl polymer is used in a concentration of 0.1 to 100%.
Claim 8
Independent Claim
27 words
The method as set forth in any of claims 1-5, wherein said sulfated vinyl polymers are administered in powder, suspension, solution, spray, emulsion, unguent or cream form.
References Cited (Backward Citations)
US3466365A
Cited
US4762715A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-06 | 1996-04-06 | 1996-10-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-06 | 2000-04-06 | 2000-10-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-06 | 2004-04-06 | 2004-10-06 | $7700.00 | Window Closed / Lapsed |